Results 11 to 20 of about 220,176 (131)

Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends [PDF]

Molecules, 2018
Currently licensed glycoconjugate vaccines are composed of a carbohydrate moiety covalently linked to a protein carrier. Polysaccharides are T-cell independent antigens able to directly stimulate B cells to produce antibodies.
Francesca Micoli, Roberto Adamo, Paolo Costantino   +2 more
doaj   +3 more sources

Recombinant production platform for Group A Streptococcus glycoconjugate vaccines [PDF]

npj Vaccines
Group A Streptococcus (Strep A) is a human-exclusive bacterial pathogen killing annually more than 500,000 patients, and no current licensed vaccine exists.
Sowmya Ajay Castro, Ian J. Passmore, Didier Ndeh, Helen Alexandra Shaw, Alessandro Ruda, Keira Burns, Sarah Thomson, Rupa Nagar, Kathirvel Alagesan, Mark Reglinski, Kieron Lucas, Sherif Abouelhadid, Ulrich Schwarz-Linek, Fatme Mawas, Göran Widmalm, Brendan W. Wren, Helge C. Dorfmueller   +16 more
doaj   +3 more sources

Modular Combinatorial DNA Assembly of Group B Streptococcus Capsular Polysaccharide Biosynthesis Pathways to Expediate the Production of Novel Glycoconjugate Vaccines [PDF]

Vaccines
Background/objectives: Streptococcus agalactiae (or Group B Streptococcus, GBS) is a major cause of neonatal meningitis globally. There are 10 serotypes of GBS, which are distinguished by their capsular polysaccharide (CPS) structure, with serotypes Ia ...
Mark A. Harrison, Elizabeth Atkins, Alexandra Faulds-Pain, John T. Heap, Brendan W. Wren, Ian J. Passmore   +5 more
doaj   +4 more sources

Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines [PDF]

Molecules, 2018
Many malignant cell surface carbohydrates resulting from abnormal glycosylation patterns of certain diseases can serve as antigens for the development of vaccines against these diseases.
Qingjiang Li, Zhongwu Guo
doaj   +3 more sources

Glycoconjugate vaccines against antimicrobial resistant pathogens [PDF]

Expert Review of Vaccines, 2023
Introduction Antimicrobial resistance (AMR) is responsible for the death of millions worldwide and stands as a major threat to our healthcare systems, which are heavily reliant on antibiotics to fight bacterial infections.
Charlotte Sorieul, Marta Dolce, Maria Rosaria Romano, Jeroen Codée, Roberto Adamo   +4 more
doaj   +2 more sources

Recent and Future Advances in the Chemoenzymatic Synthesis of Homogeneous Glycans for Bacterial Glycoconjugate Vaccine Development

Vaccines, 2021
Vaccines are important in preventing disease outbreaks and controlling the spread of disease in a population. A variety of vaccines exist, including subunit, recombinant, and conjugate vaccines.
Ayobami Adegbite, Pumtiwitt C. McCarthy
doaj   +2 more sources

GMMA Is a Versatile Platform to Design Effective Multivalent Combination Vaccines

Vaccines, 2020
Technology platforms are an important strategy to facilitate the design, development and implementation of vaccines to combat high-burden diseases that are still a threat for human populations, especially in low- and middle-income countries, and to ...
Francesca Micoli, Renzo Alfini, Roberta Di Benedetto, Francesca Necchi, Fabiola Schiavo, Francesca Mancini, Martina Carducci, Elena Palmieri, Cristiana Balocchi, Gianmarco Gasperini, Brunella Brunelli, Paolo Costantino, Roberto Adamo, Diego Piccioli, Allan Saul   +14 more
doaj   +2 more sources

The Shigella Vaccines Pipeline

Vaccines, 2022
Shigella is the leading cause of global diarrheal deaths that currently lacks a licensed vaccine. Shigellosis drives antimicrobial resistance and leads to economic impact through linear growth faltering.
Calman Alexander MacLennan, Stephanie Grow, Lyou-fu Ma, Andrew Duncan Steele   +3 more
doaj   +2 more sources

Recent Advances in Bioconjugate Vaccine Development [PDF]

Vaccines
Glycoconjugate vaccines, consisting of a protein component covalently linked to a glycan antigen, have led to a significant reduction in the global occurrence of bacterial meningitis and pneumonia. They provide robust, lasting immunity in all age groups.
Brendan W. Wren, Catherine L. Hall, Vanessa S. Terra, Mark A. Harrison, Elizabeth Atkins, Fauzy Nasher, Ian J. Passmore   +6 more
doaj   +2 more sources

Development and evaluation of a dual-target glycoconjugate against Shigella sonnei [PDF]

Frontiers in Immunology
IntroductionShigellosis morbidity and mortality, combined with the increase in multidrug-resistant infections, make Shigella vaccine development a global imperative.
Catherine L. Hall, Tom L. Flood, Simon Clare, Katherine Harcourt, Emily J. Kay, Stephen Baker, Brendan W. Wren   +6 more
doaj   +2 more sources